About
Oncolytic Vaccines
Areas of Focus
Categories
Biologics & BiopharmaceuticalVaccineAntibody
Clinical Trials (13)
View allTotal Trials
13
As Lead Sponsor
11
As Collaborator
2
Total Enrollment
819
By Phase
PHASE1: 11PHASE1/PHASE2: 1PHASE2: 1
By Status
COMPLETED: 10ACTIVE_NOT_RECRUITING: 2RECRUITING: 1
Clinical Trials Pipeline13 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06459869Lead Sponsor
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
PHASE1Recruiting
30 participants
Started: Apr 7, 2025 · Completed: Jan 30, 2029
NCT05165433Lead Sponsor
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
PHASE1Active, not recruiting
198 participants
Started: Apr 13, 2022 · Completed: Aug 29, 2025
NCT05043714Lead Sponsor
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
PHASE1Completed
30 participants
Started: Dec 1, 2021 · Completed: Oct 4, 2024
NCT04830592Lead Sponsor
A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck
PHASE1Completed
36 participants
Started: Nov 4, 2021 · Completed: Oct 4, 2024
NCT04787991Collaborator
Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
PHASE1Active, not recruiting
45 participants
Started: Aug 9, 2021 · Completed: Jan 11, 2025
Locations (1)
Headquarters
Abingdon, UK
Map
Loading map...